Dipeptidyl Peptidase-4 Inhibitors Market By Product (Single-Agent DPP-4 Inhibitors, Fixed-Dose Combination Products); By Drug Type (Sitagliptin, Linagliptin, Saxagliptin, Alogliptin, Vildagliptin, Teneligliptin, Anagliptin, Gemigliptin, Other DPP-4 Inhibitors); By Application (Type 2 Diabetes Mellitus, Combination Glucose-Lowering Therapy); By End User (Retail and Community Pharmacies, Hospital Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Dipeptidyl Peptidase-4 Inhibitors (DDP 4) Market: The Generic Transition Reshapes Pricing, Prescribing and Competitive Value

The Global Dipeptidyl Peptidase-4 Inhibitors Market was valued at USD 12.05 billion in 2025 and is projected to reach USD 14.42 billion by 2032, expanding at a CAGR of 2.6% during 2026–2032, according to Strategic Market Research.

 

Dipeptidyl peptidase-4 (DPP-4) inhibitors, also known as gliptins, are a class of oral antidiabetic drugs used mainly for the management of type 2 diabetes mellitus. They work by inhibiting the DPP-4 enzyme, which increases the activity of incretin hormones such as GLP-1 and GIP. This enhances glucose-dependent insulin secretion, suppresses glucagon release, and helps improve blood glucose control. Drugs like sitagliptin, saxagliptin, linagliptin, and alogliptin are commonly used and are preferred due to their low risk of hypoglycemia and neutral effect on body weight.

 

From Diabetes Prevalence to Prescription Revenue: Defining the Addressable DPP-4 Market

The United States had approximately 40.1 million people with diabetes in 2023, including 28.8 million adults with diagnosed diabetes and 11.0 million adults whose condition remained undiagnosed. The CDC states that type 2 diabetes represents around 90% to 95% of diabetes cases.

Applying this share to the diagnosed adult population gives an analyst-derived range of approximately 25.9 million to 27.4 million diagnosed US adults with type 2 diabetes. This broad treatment pool is considerably larger than the population that ultimately receives a DPP-4 inhibitor.

Many patients remain on lifestyle management or metformin, while others receive SGLT2 inhibitors, GLP-1 receptor agonists, sulfonylureas or insulin. Cardiovascular disease, chronic kidney disease, weight-management goals, payer restrictions, treatment switching and patient cost-sharing all influence whether a DPP-4 product is selected and continued.

 

Approved Gliptins and Their Commercial Footprint

Sitagliptin: Marketed by Merck through Januvia, Janumet and Janumet XR, sitagliptin represents the largest publicly documented commercial franchise in the class. Global Januvia and Janumet sales increased from US$2.268 billion in 2024 to US$2.544 billion in 2025, representing year-on-year growth of approximately 12.2%. The 2025 franchise revenue was equivalent to about 21.1% of the estimated global DPP-4 inhibitors market. Sales then fell by 28% year on year to US$574 million in Q1 2026 as lower US demand and net pricing combined with generic competition in international markets. Sitagliptin’s importance makes its exclusivity transition central to the overall market contraction.

Linagliptin: Marketed as Tradjenta in the United States and Trajenta in several international markets, linagliptin is mainly eliminated through non-renal pathways and generally does not require dose adjustment for renal impairment. This gives it a defined position among selected older adults and patients with reduced kidney function. Its commercial performance increasingly depends on public reimbursement, branded price reductions and competition from lower-cost alternatives.

Saxagliptin: Sold under the Onglyza brand and through combination products, saxagliptin is an established FDA-approved DPP-4 inhibitor. Its position has weakened as generics have expanded and competing diabetes medicines offering cardiovascular, kidney or weight-related benefits have gained greater treatment priority.

Alogliptin: Marketed under the Nesina brand, alogliptin is available as a single-agent medicine and in fixed-dose combinations. Its demand is influenced by generic availability, formulary placement and acquisition cost rather than strong within-class differentiation.

Vildagliptin: Marketed as Galvus, vildagliptin is authorised in Europe and several international markets but is not part of the US product mix. Novartis reported Galvus Group sales of US$487 million in 2025, equivalent to approximately 4.0% of the estimated global DPP-4 inhibitors market. Revenue declined by 19% in reported currency, reflecting continuing competition and reduced branded value.

Teneligliptin: Sold as Tenelia and through regional brands, teneligliptin is established in Japan and parts of Asia. Its regional availability broadens the class beyond the molecules that dominate the United States and Europe, while local generic competition makes the segment highly price-sensitive.

Anagliptin: Marketed as Suiny, anagliptin is primarily associated with Japan. Its commercial reach is narrower than that of sitagliptin or linagliptin, but it adds to the wider range of domestically approved DPP-4 options available in Asian markets.

Gemigliptin: Developed in South Korea and marketed as Zemiglo, gemigliptin is also available in combinations with metformin or dapagliflozin. Its role remains concentrated in South Korea and selected emerging markets rather than major US or European reimbursement channels.

 

Medicare’s Price Reset Redefines Branded Product Economics

CMS recorded approximately 843,000 Medicare Part D enrollees using Januvia in 2023, with US$4.091 billion in gross covered prescription costs. From 2026, Medicare’s negotiated price was set at US$113 for a 30-day supply, compared with a referenced 2023 list price of US$527, representing a 79% reduction.

Linagliptin is entering a similar pricing transition. Tradjenta was used by approximately 274,000 Medicare Part D enrollees and generated US$1.128 billion in gross covered costs during 2024. Its negotiated Medicare price will be US$78 per 30-day supply from 2027, an 84% reduction from the referenced 2024 list price.

These lower reimbursement benchmarks change the economics of two major branded products. They improve payer affordability and may help preserve access, but they also reduce revenue per treated patient and strengthen commercial pressure on originators. Public price negotiation may also influence commercial insurance discussions and future formulary decisions beyond Medicare.

 

The Sitagliptin Patent Cliff Opens a Generic-Led Market

The FDA approved the first generic sitagliptin tablets referencing Januvia in December 2025. It also approved the first generic sitagliptin–metformin products referencing Janumet and Janumet XR during 2025. These approvals establish the basis for pharmacy substitution, payer-preferred placement and lower-cost access across major sitagliptin segments.

Merck disclosed US exclusivity transitions in May 2026 for Januvia and Janumet and July 2026 for Janumet XR. Commercial value is consequently shifting from originator intellectual property towards generic manufacturing scale, wholesaler access, pharmacy availability and supply reliability.

Generic suppliers are likely to compete mainly through price, substitution status and formulary access. Branded sales can fall rapidly even when prescription volume remains relatively stable, meaning the market may continue serving a sizeable patient base while total revenue contracts. This value shift is one of the main reasons the market is projected to decline through 2032.

 

Combination Therapies Defend Prescription Volume, Not Premium Pricing

Fixed-dose combinations allow patients requiring more than one glucose-lowering medicine to receive treatment through a single tablet. Established products combine DPP-4 inhibitors with metformin, while newer formulations pair them with SGLT2 inhibitors.

Janumet and Janumet XR were used by approximately 239,000 Medicare Part D enrollees in 2024 and generated US$1.068 billion in gross covered costs. Their negotiated Medicare price will be US$80 per 30-day supply from 2027, compared with a referenced 2024 list price of US$526, representing a reduction of approximately 85%.

Australia provides an early indicator for the SGLT2–DPP-4 combination segment. Dapagliflozin–sitagliptin generated 5,177 subsidised prescriptions and A$316,895 in government expenditure during 2024–25 after its November 2024 listing.

 

The Innovation Pipeline Moves Towards Longer Dosing and Smarter Combinations

The DPP-4 development landscape is mature, with activity increasingly focused on longer-acting medicines and fixed-dose combinations rather than entirely new mechanisms.

Cofrogliptin, also known as HSK7653, was developed as an ultra-long-acting DPP-4 inhibitor with once-every-two-weeks dosing and received regulatory approval in China in February 2025. Its progress shows that selected regional manufacturers continue to see value in reducing dosing frequency and differentiating established oral treatment.

Tirzepatide is not part of the DPP-4 pipeline. It is a dual GIP and GLP-1 receptor agonist that competes with DPP-4 inhibitors through a different mechanism and offers stronger effects on glucose and body weight. NICE advises against combining a DPP-4 inhibitor with a GLP-1 receptor agonist or tirzepatide.

Research involving DPP-4, also known as CD26, in inflammatory and immune pathways may create longer-term scientific opportunities. Commercial inclusion will depend on the development of clearly defined products with regulatory progress outside type 2 diabetes.

 

Guideline Sequencing Narrows the Market’s Growth Corridor

DPP-4 inhibitors retain a place in type 2 diabetes care because they provide an oral, generally weight-neutral option with a low intrinsic risk of hypoglycaemia. Their role is narrower when patients have cardiovascular disease, chronic kidney disease or strong weight-reduction needs.

SGLT2 inhibitors and GLP-1-based medicines are increasingly prioritised for patients requiring broader cardiovascular, kidney or weight outcomes. This reduces new DPP-4 treatment initiation even when existing users continue to generate repeat prescriptions.

The market therefore faces two forms of competition. Generic suppliers compete for prescriptions within the DPP-4 class, while SGLT2 and GLP-1-based therapies compete for the patient before a DPP-4 medicine is selected. This treatment shift places structural pressure on class revenue beyond the direct effect of genericisation.

 

Regional Demand Signals Reveal Uneven Pricing and Product-Mix Pressure

North America is the centre of the current pricing and generic transition. Medicare negotiation, FDA generic approvals and the sitagliptin exclusivity change are moving the US market towards lower-priced products and stronger payer control.

Europe continues to include DPP-4 inhibitors within reimbursed treatment pathways, but acquisition cost and treatment sequencing increasingly affect molecule selection. Vildagliptin and its combinations give Europe a broader product mix than the United States.

Asia-Pacific has a wider range of regional DPP-4 products and locally manufactured alternatives. Australia recorded 866,746 subsidised Trajenta prescriptions and A$52.109 million in total reimbursed cost during 2024–25, demonstrating substantial recurring linagliptin use in a mature public-benefit system. Japan, South Korea, China and India also support demand for regionally established molecules and lower-cost generics.

 

Competitive Advantage Shifts From Brand Power to Price and Supply

Merck remains the most visible originator through Januvia and Janumet. Boehringer Ingelheim and Eli Lilly participate through linagliptin products, while Novartis, AstraZeneca and Takeda have competed through vildagliptin, saxagliptin and alogliptin portfolios.

Watson Laboratories, Sandoz, PH Health and other generic suppliers are becoming more important as sitagliptin and its combinations lose exclusivity. Their performance will depend on competitive production costs, substitutable product status, formulary placement, wholesaler access, pharmacy coverage and reliable supply.

Prescribers initiate demand, but payers and formularies increasingly influence which molecule is covered, while pharmacists may determine the final manufacturer when substitution is permitted. As differentiation within the class narrows, procurement decisions are becoming more price-led and supply-led.

 

The 2032 Outlook: Stable Treatment Demand Meets Continuing Revenue Erosion

The main commercial risk is the combined pressure from generic entry, lower negotiated reimbursement and competing treatment classes. Originators may retain selected patients through recognised brands, established combinations and molecule-specific prescribing positions, but branded revenue will remain exposed to price erosion.

Generic manufacturers gain access to a large prescription base, although intense competition can narrow margins. Reliable supply, pharmacy availability and favourable formulary placement will be as important as regulatory approval.

Recurring treatment provides resilience among patients who remain clinically suited to DPP-4 medicines. However, the market’s future value will be shaped more by unit-price reduction, generic mix and treatment switching than by growth in diabetes prevalence alone.

The forecast contraction reflects value redistribution rather than the disappearance of clinical demand. Prescription volume may remain meaningful, but revenue is moving away from high-priced originator brands towards generics, cost-controlled combinations and payer-preferred products. SGLT2 and GLP-1-based therapies will continue to restrict wider class expansion.

 

Dipeptidyl Peptidase-4 Inhibitors (DDP 4) Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 12.05 Billion
Revenue Forecast in 2032	USD 14.42 Billion
Overall Growth Rate	CAGR of 2.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Drug Type, By Application, By End User, By Geography
By Product	Single-Agent DPP-4 Inhibitors, Fixed-Dose Combination Products
By Drug Type	Sitagliptin, Linagliptin, Saxagliptin, Alogliptin, Vildagliptin, Teneligliptin, Anagliptin, Gemigliptin, Other DPP-4 Inhibitors
By Application	Type 2 Diabetes Mellitus, Combination Glucose-Lowering Therapy
By End User	Retail and Community Pharmacies, Hospital Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	• Rising global prevalence of Type 2 diabetes and increasing demand for effective glucose management therapies. • Growing adoption of combination diabetes treatment approaches to improve glycemic control. • Expanding access to oral anti-diabetic medicines through retail and online pharmacy channels.
Customization Option	Available upon request